Literature DB >> 36203040

Mouse organoids as an in vitro tool to study the in vivo intestinal response to cytotoxicants.

F Jardi1, C Kelly2, C Teague3, H Fowler-Williams2, D C Sevin4, D Rodrigues5, H Jo6, S Ferreira6, B Herpers7, M Van Heerden8, T de Kok5, C Pin9, A Lynch3, C A Duckworth2, S De Jonghe8, L Lammens8, D M Pritchard2.   

Abstract

Cross-species comparison of drug responses at the organoid level could help to determine the human relevance of findings from animal studies. To this end, we first need to evaluate the in vitro to in vivo translatability of preclinical organoids. Here, we used 5-fluorouracil (5-FU) as an exemplar drug to test whether the in vivo gut response to this cytotoxicant was preserved in murine intestinal organoids. Mice treated with 5-FU at 20 or 50 mg/kg IV (low and high dose, respectively) displayed diarrhea at clinically relevant exposures. 5-FU also induced intestinal lesions, increased epithelial apoptosis, and decreased proliferation in a dose-dependent manner. To enable comparison between the in vitro and in vivo response, top nominal in vitro drug concentrations that caused significant cytotoxicity were chosen (dose range 1-1000 µM). The inferred intracellular concentration in organoids at 1000 µM was within the tissue exposure range related to intestinal toxicity in vivo. 5-FU at ≥ 100 µM decreased ATP levels and increased Caspase-3 activity in intestinal organoids. In keeping with the in vivo findings, 5-FU increased the percentage of Caspase-3-positive cells and reduced Ki67 staining. At the transcriptome level, there was an overlap in the activity of pathways related to 5-FU's mode of action, lipid and cholesterol metabolism and integrin signaling across in vivo gut and organoids. The predicted activity state of upstream regulators was generally well preserved between setups. Collectively, our results suggest that despite their inherent limitations, organoids represent an adequate tool to explore the intestinal response to cytotoxicants.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Drug-induced intestinal toxicity; Organoids; PBPK; Preclinical species; Transcriptomics

Year:  2022        PMID: 36203040     DOI: 10.1007/s00204-022-03374-3

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   6.168


  47 in total

Review 1.  Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction.

Authors:  Pascal Crenn; Bernard Messing; Luc Cynober
Journal:  Clin Nutr       Date:  2008-04-28       Impact factor: 7.324

2.  Introduction to a manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications.

Authors:  Kristin Fabre; Brian Berridge; William R Proctor; Sherry Ralston; Yvonne Will; Szczepan W Baran; Gorm Yoder; Terry R Van Vleet
Journal:  Lab Chip       Date:  2020-03-17       Impact factor: 6.799

Review 3.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.

Authors:  David Cook; Dearg Brown; Robert Alexander; Ruth March; Paul Morgan; Gemma Satterthwaite; Menelas N Pangalos
Journal:  Nat Rev Drug Discov       Date:  2014-05-16       Impact factor: 84.694

4.  Human ileal organoid model recapitulates clinical incidence of diarrhea associated with small molecule drugs.

Authors:  David G Belair; Richard J Visconti; Miyoun Hong; Mathieu Marella; Matthew F Peters; Clay W Scott; Kyle L Kolaja
Journal:  Toxicol In Vitro       Date:  2020-07-03       Impact factor: 3.500

5.  Manuka honey synergistically enhances the chemopreventive effect of 5-fluorouracil on human colon cancer cells by inducing oxidative stress and apoptosis, altering metabolic phenotypes and suppressing metastasis ability.

Authors:  Sadia Afrin; Francesca Giampieri; Tamara Y Forbes-Hernández; Massimiliano Gasparrini; Adolfo Amici; Danila Cianciosi; Josè L Quiles; Maurizio Battino
Journal:  Free Radic Biol Med       Date:  2018-07-26       Impact factor: 7.376

6.  Cell adhesion molecules are altered during irinotecan-induced mucositis: a qualitative histopathological study.

Authors:  Noor Al-Dasooqi; Joanne Bowen; Colin Bennett; John Finnie; Dorothy Keefe; Rachel Gibson
Journal:  Support Care Cancer       Date:  2016-09-20       Impact factor: 3.603

7.  First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.

Authors:  J Cassidy; C Twelves; E Van Cutsem; P Hoff; E Bajetta; M Boyer; R Bugat; U Burger; A Garin; U Graeven; J McKendric; J Maroun; J Marshall; B Osterwalder; G Pérez-Manga; R Rosso; P Rougier; R L Schilsky
Journal:  Ann Oncol       Date:  2002-04       Impact factor: 32.976

8.  Identification of stem cells in small intestine and colon by marker gene Lgr5.

Authors:  Nick Barker; Johan H van Es; Jeroen Kuipers; Pekka Kujala; Maaike van den Born; Miranda Cozijnsen; Andrea Haegebarth; Jeroen Korving; Harry Begthel; Peter J Peters; Hans Clevers
Journal:  Nature       Date:  2007-10-14       Impact factor: 49.962

9.  Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery.

Authors:  Paula M De Angelis; Debbie H Svendsrud; Katherine L Kravik; Trond Stokke
Journal:  Mol Cancer       Date:  2006-05-18       Impact factor: 27.401

10.  Trimmomatic: a flexible trimmer for Illumina sequence data.

Authors:  Anthony M Bolger; Marc Lohse; Bjoern Usadel
Journal:  Bioinformatics       Date:  2014-04-01       Impact factor: 6.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.